Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.2M Buy
94,992
+5,736
+6% +$671K 0.45% 33
2026
Q1
$10.7M Buy
89,256
+8,626
+11% +$996K 0.5% 25
2025
Q4
$8.49M Buy
80,630
+11,819
+17% +$1.11M 0.43% 27
2025
Q3
$5.78M Buy
68,811
+11,047
+19% +$910K 0.32% 44
2025
Q2
$4.57M Buy
57,764
+9,497
+20% +$755K 0.29% 43
2025
Q1
$4.33M Buy
48,267
+5,337
+12% +$498K 0.33% 51
2024
Q4
$4.27M Sell
42,930
-2,488
-5% -$256K 0.36% 36
2024
Q3
$5.16M Buy
45,418
+6,007
+15% +$714K 0.51% 28
2024
Q2
$4.88M Buy
39,411
+10,299
+35% +$1.33M 0.66% 19
2024
Q1
$3.84M Buy
29,112
+4,481
+18% +$552K 0.78% 18
2023
Q4
$2.97M Buy
+24,631
New +$2.56M 0.81% 17

Other funds holding MRK

GAMMA Investing's MRK Position: Q2 2026 in Review

GAMMA Investing increased its Merck (MRK) stake by 6.4% in Q2 2026, buying an estimated $671K and bringing the position to 94,992 shares worth $12.2M. The position accounts for 0.45% of the portfolio, ranked #33.

GAMMA Investing first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 1,299 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • GAMMA Investing held 94,992 shares of Merck worth $12.2M as of Q2 2026.
  • GAMMA Investing bought 5,736 Merck shares in Q2 2026, an estimated $671K.
  • Merck made up 0.45% of GAMMA Investing's portfolio in Q2 2026, its #33 holding.
  • GAMMA Investing first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 1,299 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.